Moreover, hyperglycemia enhances ipilimumab-induced cardiotoxicity through mechanisms mediated by MyD88 and NLRP3 signaling7, suggesting that targeting the MyD88/NLRP3 signaling may inhibit ipilimumab-induced cardiotoxicity in patients with cardiovascular diseases. Here, NLRP3 is linked to cardiovascular disorder.